BioTime (BTX) Posts Q3 EPS of 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to BioTime (BTX) Posts Q3 EPS of 30c
November 4, 2016 7:00 AM EDT
FREMONT, Calif., Nov. 4, 2016 /PRNewswire/ --Â Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will release third quarter financial results and provide an update on clinical progress on Monday, November 14, 2016 after the close of the U.S. financial markets.
The Company will host a conference call and webcast on November 14, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Company management will be joined by Shekar N. Kurpad, MD, PhD, Professor of Neurosurgery, Director, Spinal Cord Injury Center Medical College of... More
November 3, 2016 4:01 PM EDT
Initial data from OpRegen® trial suggest
cells able to engraft and survive at least 12 months
Initial 3-D Imaging data from Renevia® trial run-in patients
suggest volumetric improvements are sustained at least 12 months
ALAMEDA, Calif.--(BUSINESS WIRE)--
BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology
company with a focus on pluripotent cell-based technologies, today
reported financial results for the third quarter ended September 30,
2016, and recent therapeutic program progress.
Through the quarter, we continued... More
